



Title Trial of Her2-expressing vaccine in dogs with appendicular osteosarcoma.

Purpose Canine osteosarcoma is the most common bone tumor in dogs and frequently spreads to the lungs and other organs. Current therapies often have limited benefit. This study tests the efficacy and safety of a new type of cancer vaccine to be given following surgical treatment of limb osteosarcoma. Study patients will be randomized to either receive this vaccine or a placebo treatment.

Eligibility To be eligible for this study, dogs must meet several criteria, including but not limited to the following:

- Clinically confirmed diagnosis of appendicular osteosarcoma cancer.
- Must be able to bring pet back for regularly scheduled recheck visits.

For more information about this study and to inquire about eligibility and potential study benefits, please contact Nicole Leibman, DVM, DACVIM (Oncology) 212-329-8696 or 212-329-8740 (nicole.leibman@amcny.org).